HGEN News and Press, Humanigen Inc. From 12/01/21

Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients 1 Per the paper, the implication from all the available evidence is that “Lenzilu...

Abstract #S48 describes top-line results from the Humanigen Phase 3 LIVE-AIR study in hospitalized COVID-19 patients, which reveal a 54% relative improvement in the likelihood of survival without invasive mechanical ventilation (“SWOV”) in lenzilumab-treated patients com...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that its presentation time at the Jefferies London Healthcare Conference ha...

Humanigen (NASDAQ:HGEN): Q3 GAAP EPS of -$1.12 misses by $0.14. Revenue of $1.04M beats by $0.97M. Press Release As of September 30, 2021, the company had cash and cash equivalents of $76.5 million. Subsequent to September 30, 2021, the company received net proceeds of approximately $24.5 mil...

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‛cytokine storm’ with its lead drug candidate, lenzilumab, today provided a corporate and regulatory update and reporte...

Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The “Risk Adapted Therapy in Acute GvHD”, or “RATinG”, study is expe...

SRAX hosted the 2021 LD Micro Main Event between October 12-14, 2021 Marking a return to an in-person conference after nearly 2 years, the event was held at both, Los Angeles’ Luxe Sunset Bel Air Hotel as well as in a virtual format The conference featured 139 companies in atte...

Abstract #2777 describes preclinical models that demonstrate GM-CSF neutralization with lenzilumab improves CAR-T cell proliferation, but blocking the GM-CSFα receptor may inhibit CAR-T cell proliferation Abstract #1758 describes the Phase 3 SHIELD study, which is planned t...

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced that management will present and participate at multiple investors conferen...

Earlier studies have shown the granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing effect of lenzilumab may benefit CMML patients with RAS pathway mutations Study is intended to build on evidence that certain CMML patients have mutations associated with hyper-pr...